Boehringer launches open innovation project for work-at-home scientistsGermany’s Boehringer Ingelheim is to make a bank of its molecules available to scientists in a bid to Share XBoehringer launches open innovation project for work-at-home scientistshttps://pharmaphorum.com/r-d/news-r-d/boehringer-launches-open-innovation-project-for-work-at-home-scientists/
BI opens second branch of digital lab in ChinaBoehringer Ingelheim has announced that it will open a second branch of its digital lab, BI X, in Share XBI opens second branch of digital lab in Chinahttps://pharmaphorum.com/news/bi-opens-branch-of-digital-lab-in-china/
FDA fast-tracks Lilly/Boehringer’s Jardiance in chronic kidney diseaseThe FDA has granted a speedy review of Eli Lilly and Boehringer Ingelheim’s Jardiance for a potential new Share XFDA fast-tracks Lilly/Boehringer’s Jardiance in chronic kidney diseasehttps://pharmaphorum.com/news/fda-fast-tracks-lilly-boehringers-jardiance-in-chronic-kidney-disease/
Boehringer launches digital platform to raise awareness about trialsBoehringer Ingelheim and Carebox Healthcare Solutions have launched a digital platform aimed at giving patients, families, caregivers and Share XBoehringer launches digital platform to raise awareness about trialshttps://pharmaphorum.com/news/bi-launches-digital-platform-to-raise-awareness-about-trials/
Boehringer bags CHMP backing for Ofev in rare lung diseaseBoehringer Ingelheim has moved a step closer to getting approval for its blockbuster respiratory drug Ofev as the Share XBoehringer bags CHMP backing for Ofev in rare lung diseasehttps://pharmaphorum.com/news/boehringer-bags-chmp-backing-for-ofev-in-rare-lung-disease/
Lilly, Boehringer bag FDA okay for diabetes triple Trijardy XREli Lilly and Boehringer Ingelheim’s longstanding alliance in diabetes has delivered another new product, this time a three-drug Share XLilly, Boehringer bag FDA okay for diabetes triple Trijardy XRhttps://pharmaphorum.com/news/lilly-boehringer-bag-fda-okay-for-diabetes-triple-trijardy-xr/
BI buys rights to NASH-targeted tech from Singapore’s EnleofenBoehringer Ingelheim has bought rights to preclinical technology aimed at fibro-inflammatory diseases including the fatty liver disease known Share XBI buys rights to NASH-targeted tech from Singapore’s Enleofenhttps://pharmaphorum.com/news/bi-buys-rights-to-nash-targeted-tech-from-singapores-enleofen/
Boehringer cleared to manufacture BeiGene’s cancer drug for Chinese marketBoehringer Ingelheim is to manufacture the first biologic drug approved in China using a new regulatory system, designed Share XBoehringer cleared to manufacture BeiGene’s cancer drug for Chinese markethttps://pharmaphorum.com/news/boehringer-gets-clearance-to-manufacture/
Boehringer, Lilly start acute heart failure trial with JardianceBoehringer and Eli Lilly have started a large-scale trial of their diabetes drug Jardiance in acute heart failure, Share XBoehringer, Lilly start acute heart failure trial with Jardiancehttps://pharmaphorum.com/news/boehringer-lilly-start-acute-heart-failure-trial-with-jardiance/
